Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HILSNASDAQ:LIXTNASDAQ:PULMNASDAQ:SONN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHILSHillstream BioPharma$1.51+1.3%$1.36$0.19▼$2.65$26.58M3.081.39 million shs6,298 shsLIXTLixte Biotechnology$1.28+5.3%$1.23$1.02▼$3.50$4.03M0.4185,786 shs6,294 shsPULMPulmatrix$6.26+1.0%$6.54$1.72▼$10.40$22.85M1.38131,821 shs21,200 shsSONNSonnet BioTherapeutics$1.33+3.9%$1.33$1.10▼$16.00$4.08M0.95380,139 shs26,262 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHILSHillstream BioPharma0.00%-1.31%+42.45%-20.53%+301.49%LIXTLixte Biotechnology+5.26%+0.79%+5.87%-33.68%-50.00%PULMPulmatrix+0.98%-2.32%+15.94%-16.41%+251.74%SONNSonnet BioTherapeutics+3.91%+3.10%+3.10%-15.29%-21.76%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHILSHillstream BioPharmaN/AN/AN/AN/AN/AN/AN/AN/ALIXTLixte Biotechnology0.9764 of 5 stars0.05.00.00.03.10.80.0PULMPulmatrix0.7919 of 5 stars0.05.00.00.03.30.00.0SONNSonnet BioTherapeutics1.5273 of 5 stars3.52.00.00.02.70.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHILSHillstream BioPharma 0.00N/AN/AN/ALIXTLixte Biotechnology 0.00N/AN/AN/APULMPulmatrix 0.00N/AN/AN/ASONNSonnet BioTherapeutics 3.00Buy$20.001,403.76% UpsideCurrent Analyst Ratings BreakdownLatest SONN, PULM, LIXT, and HILS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/7/2025SONNSonnet BioTherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.003/28/2025SONNSonnet BioTherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHILSHillstream BioPharmaN/AN/AN/AN/A$0.48 per shareN/ALIXTLixte BiotechnologyN/AN/AN/AN/A$0.22 per shareN/APULMPulmatrix$7.81M2.93N/AN/A$4.93 per share1.27SONNSonnet BioTherapeutics$1M4.08N/AN/A$1.32 per share1.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHILSHillstream BioPharma-$8.47M-$0.72N/AN/AN/AN/A-188.44%-149.61%N/ALIXTLixte Biotechnology-$5.09M-$1.59N/A∞N/AN/A-5,562.77%-130.48%N/APULMPulmatrix-$14.12M-$2.61N/A∞N/A-96.51%-45.97%-30.72%N/ASONNSonnet BioTherapeutics-$7.44MN/A0.00∞N/AN/A-408.93%-174.13%5/13/2025 (Estimated)Latest SONN, PULM, LIXT, and HILS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q2 2025SONNSonnet BioTherapeutics-$0.92N/AN/AN/AN/AN/A5/12/2025Q1 2025LIXTLixte BiotechnologyN/A-$0.29N/A-$0.29N/AN/A3/24/2025Q4 2024LIXTLixte BiotechnologyN/A-$0.27N/A-$0.27N/AN/A3/21/2025Q4 2024PULMPulmatrixN/A-$0.54N/A-$0.54N/AN/A2/13/2025Q1 2025SONNSonnet BioTherapeutics-$11.12-$1.56+$9.56-$1.56N/A$1,000.00 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHILSHillstream BioPharmaN/AN/AN/AN/AN/ALIXTLixte BiotechnologyN/AN/AN/AN/AN/APULMPulmatrixN/AN/AN/AN/AN/ASONNSonnet BioTherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHILSHillstream BioPharmaN/A3.013.01LIXTLixte BiotechnologyN/A5.135.13PULMPulmatrixN/A19.4019.40SONNSonnet BioTherapeuticsN/A2.152.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHILSHillstream BioPharma13.36%LIXTLixte Biotechnology5.10%PULMPulmatrix11.84%SONNSonnet BioTherapeutics9.45%Insider OwnershipCompanyInsider OwnershipHILSHillstream BioPharma30.24%LIXTLixte Biotechnology14.80%PULMPulmatrix0.62%SONNSonnet BioTherapeutics2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHILSHillstream BioPharma117.60 million12.28 millionNot OptionableLIXTLixte Biotechnology43.15 million1.92 millionNot OptionablePULMPulmatrix203.65 million3.63 millionNot OptionableSONNSonnet BioTherapeutics103.07 million3.01 millionNot OptionableSONN, PULM, LIXT, and HILS HeadlinesRecent News About These CompaniesSonnet BioTherapeutics (SONN) Projected to Post Earnings on TuesdayMay 12 at 2:49 AM | americanbankingnews.comSonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development SummitMay 1, 2025 | globenewswire.comSonnet Releases Virtual Investor "What This Means" SegmentApril 16, 2025 | globenewswire.comAir Traffic Controllers Lost Contact With Doomed Pilot Shortly After Takeoff: NTSBApril 11, 2025 | franklinreporter.comSonnet BioTherapeutics reports positive results from ovarian cancer therapy trialApril 7, 2025 | msn.comSonnet BioTherapeutics Reports Positive Phase 1b/2a Data For SON-1010April 6, 2025 | nasdaq.comSonnet BioTherapeutics advances in cancer trialApril 6, 2025 | uk.investing.comSonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at ...April 6, 2025 | seekingalpha.comSonnet Biotherapeutics Holdings Inc trading halted, news pendingApril 4, 2025 | markets.businessinsider.comSonnet says SON-1010 demonstrates ‘strong safety profile’ in atezolizumab comboApril 4, 2025 | markets.businessinsider.comSonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest DoseApril 4, 2025 | globenewswire.comSonnet BioTherapeutics appoints interim CEO and new presidentApril 3, 2025 | investing.comSonnet BioTherapeutics Names Raghu Rao Interim CEO As Founder PassesApril 3, 2025 | nasdaq.comPilot Killed In NJ Crash Was CEO Of Cancer-Focused Biotech CompanyApril 3, 2025 | msn.comDeadly plane crash in NJ neighborhood sounds like bomb explosionApril 2, 2025 | nj1015.comLawrenceville Man Piloted Plane That Crashed In Six Mile Run; Flight Lasted 5 MinutesApril 2, 2025 | franklinreporter.comPilot Killed In Franklin Twp Plane Crash Was CEO Of Cancer-Focused Biotech CompanyApril 2, 2025 | msn.comSonnet BioTherapeutics announces passing of founder, CEO Pankaj MohanApril 2, 2025 | markets.businessinsider.comSonnet Announces Release of Corporate Update VideoApril 1, 2025 | globenewswire.comPilot killed in N.J. plane crash was biotech company founder, CEOApril 1, 2025 | nj.comMedia Sentiment Over TimeSONN, PULM, LIXT, and HILS Company DescriptionsHillstream BioPharma NASDAQ:HILS$1.51 +0.02 (+1.34%) As of 05/9/2025Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.Lixte Biotechnology NASDAQ:LIXT$1.27 +0.06 (+4.85%) As of 05/12/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.Pulmatrix NASDAQ:PULM$6.26 +0.06 (+0.98%) Closing price 05/12/2025 03:57 PM EasternExtended Trading$6.58 +0.32 (+5.03%) As of 07:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.Sonnet BioTherapeutics NASDAQ:SONN$1.33 +0.05 (+3.91%) Closing price 05/12/2025 03:59 PM EasternExtended Trading$1.32 -0.01 (-0.45%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready Why DraftKings Share Price Could Soar to Multi-Year Highs BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
